LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Listă Acțiuni・Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Închisă

SectorSănătate

638.17 -0.53

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

633.36

Maxim

642.52

Indicatori cheie
By Trading Economics
Venit	-117M 727M
Vânzări	-279M 3.6B
P/E Medie Sector	15.384 49.701
EPS	9.47
Randament dividend	0.51
Marjă de profit	20.17
Angajați	15,343
EBITDA	-234M 967M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+29.13% upside

Dividende
By Dow Jones
Randament dividend Medie Sector	0.51% 2.39%
Următoarele câștiguri	31 iul. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-12B 66B
Deschiderea anterioară	638.7
Închiderea anterioară	638.17

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

542.44 / 599.76 Suport & Rezistență

Regeneron Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

1 aug. 2025, 11:33 UTC

Câștiguri

Regeneron 2Q Revenue, Adjusted EPS Top Estimates

29 apr. 2026, 12:01 UTC

Câștiguri

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

23 apr. 2026, 21:48 UTC

Achiziții, Fuziuni, Preluări

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

11 mar. 2026, 11:02 UTC

Market Talk

Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk

14 dec. 2025, 08:30 UTC

Achiziții, Fuziuni, Preluări

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

1 aug. 2025, 13:16 UTC

Câștiguri

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 aug. 2025, 12:40 UTC

Câștiguri

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 aug. 2025, 10:41 UTC

Câștiguri

Regeneron Now Sees 2025 Adjusted R&D $5.1B-$5.2B; Had Seen $5B-$5.2B >REGN

1 aug. 2025, 10:41 UTC

Câștiguri

Regeneron Now Sees 2025 Capital Spending $880M-$950M; Had Seen $850M-$950M >REGN

1 aug. 2025, 10:40 UTC

Câștiguri

Regeneron Now Sees 2025 Adjusted Gross Margin on Net Product Sales About 86%; Had Seen 86%-87% >REGN

1 aug. 2025, 10:38 UTC

Câștiguri

Regeneron: Odronextamab Application Also Impacted by Site Inspection >REGN

1 aug. 2025, 10:37 UTC

Câștiguri

Regeneron Gets FDA Complete Response Letter for Odronextamab in Follicular Lymphoma >REGN

1 aug. 2025, 10:35 UTC

Câștiguri

Regeneron: Anticipate Expeditious Resolution of Filling Issues for Eylea HD >REGN

1 aug. 2025, 10:34 UTC

Câștiguri

Regeneron Cites Observations From FDA General Site Inspection at Filler for Eylea HD >REGN

1 aug. 2025, 10:33 UTC

Câștiguri

Regeneron Sees FDA Approvals Delayed for Eylea HD Indications With August Target Actio Dates >REGN

1 aug. 2025, 10:32 UTC

Câștiguri

Regeneron Pharma: About 45 Product Candidates in Clinical Development >REGN

1 aug. 2025, 10:31 UTC

Câștiguri

Regeneron Pharma 2Q Eylea HD, Eylea U.S. Net Sales Fell 25% to $1.15B >REGN

1 aug. 2025, 10:31 UTC

Câștiguri

Regeneron Pharma: 2Q Dupixent Global Net Sales Recorded by Sanofi Rose 22% to $4.34B >REGN

1 aug. 2025, 10:30 UTC

Câștiguri

Regeneron Pharma 2Q Adj EPS $12.89 >REGN

1 aug. 2025, 10:30 UTC

Câștiguri

Regeneron Pharma 2Q Rev $3.68B >REGN

1 aug. 2025, 10:30 UTC

Câștiguri

Regeneron Pharma 2Q EPS $12.81 >REGN

1 aug. 2025, 10:30 UTC

Câștiguri

Regeneron Pharma 2Q Net $1.39B >REGN

13 iun. 2025, 21:42 UTC

Achiziții, Fuziuni, Preluări

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

13 iun. 2025, 20:45 UTC

Achiziții, Fuziuni, Preluări

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

13 iun. 2025, 20:34 UTC

Achiziții, Fuziuni, Preluări

Anne Wojcicki Wins Bidding for 23andMe -- Update

13 iun. 2025, 20:14 UTC

Achiziții, Fuziuni, Preluări

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

13 iun. 2025, 20:14 UTC

Achiziții, Fuziuni, Preluări

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

13 iun. 2025, 20:14 UTC

Achiziții, Fuziuni, Preluări

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

5 iun. 2025, 01:41 UTC

Achiziții, Fuziuni, Preluări

23andMe's Former CEO Pushes Purchase Price Nearly $50 Million Higher -- WSJ

30 mai 2025, 08:58 UTC

Acțiuni populare

Stocks to Watch Friday: Dell, Marvell, Gap, Ulta -- WSJ

Comparație

Modificare preț

Regeneron Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

29.13% sus

Prognoză pe 12 luni

Medie 829.77 USD 29.13%

Maxim 995 USD

Minim 641 USD

În baza a 22 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruRegeneron Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

22 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 22 analiști care au acordat evaluări ale acțiunilor Regeneron Pharmaceuticals Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

542.44 / 599.76Suport & Rezistență

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.